The Most Quoted Number in IVF
Patients comparing fertility centres often begin with one question:
“What is your success rate?”
The question is understandable, but a single percentage cannot describe the performance of an IVF programme or predict the outcome for an individual patient.
A clinic may report pregnancy per embryo transfer, live birth per egg collection, positive pregnancy tests, or outcomes only among patients who reached a particular stage. Each calculation can produce a different number while describing the same group of treatments.
At Jinemed, success is not defined by selecting the most impressive percentage. It is understood through transparent definitions, individual patient factors, laboratory quality, treatment safety, cumulative outcomes, and the experience of patients whose treatment does not result in pregnancy.
The purpose of outcome data is to inform patients—not to create certainty where none exists.
Pregnancy Is Not the Same as Live Birth
The word “success” may refer to several different outcomes:
- A positive blood pregnancy test
- A gestational sac seen on ultrasound
- A pregnancy with fetal heartbeat
- An ongoing pregnancy
- A live birth
- A healthy singleton birth at term
These outcomes are connected, but they are not interchangeable.
A biochemical pregnancy may produce a positive blood test but end before a pregnancy is visible on ultrasound. A clinical pregnancy may later miscarry. A twin pregnancy may result in live birth but carry higher risks of premature delivery and pregnancy complications than a singleton pregnancy.
For patients, the outcome that usually matters most is taking home a healthy baby. Pregnancy rates may provide useful earlier information, but they should not be presented as though every positive test becomes a live birth.
A transparent report states exactly which outcome is being measured and how long patients were followed.
The Denominator Changes the Story
Every success percentage has a numerator and a denominator.
The numerator may be pregnancies or live births. The denominator may be:
- Cycles started
- Ovarian stimulations begun
- Egg collections performed
- Patients with eggs collected
- Embryos transferred
- Transfer procedures
- Frozen embryo transfers
- Individual embryos transferred
The choice of denominator can change the result dramatically.
Consider a group of patients beginning IVF. Some may have treatment cancelled because follicles do not develop. Some may reach egg collection but have no mature eggs. Others may have no fertilisation or no embryo suitable for transfer.
If a clinic reports success only per embryo transfer, all patients who did not reach transfer disappear from the calculation. The resulting percentage may accurately describe transfers, but it does not describe the chance of success from the beginning of treatment.
For patients with low ovarian reserve or complex histories, this distinction is especially important. Their main difficulty may occur before transfer. A high transfer success rate tells them little about the likelihood of obtaining an embryo to transfer.
At Jinemed, outcome discussions should begin by identifying the denominator, not by repeating the largest number.
Age Is Central
Maternal age is one of the strongest factors influencing IVF outcomes when a patient uses her own eggs.
Age affects both ovarian reserve and the likelihood that an embryo will have the correct chromosome number. As age increases, patients may obtain fewer eggs, fewer blastocysts, and a smaller proportion of chromosomally suitable embryos. Miscarriage risk also increases.
For this reason, a clinic-wide average combining patients in their twenties with patients in their forties is not clinically useful.
Success rates should be separated into meaningful age groups and interpreted alongside:
- Use of the patient’s own eggs
- Ovarian reserve
- Previous treatment
- Diagnosis
- Number of eggs collected
- Embryo stage and quality
- Whether embryos were genetically tested
A clinic treating a larger proportion of older patients or difficult cases may appear to have a lower overall rate even when the quality of care is high. Another clinic may improve its published number by limiting treatment to patients with a favourable prognosis.
The patient needs an estimate relevant to her own case, not the clinic’s blended marketing average.
Patient Selection Can Influence Published Results
Clinic success rates do not reflect laboratory and medical quality alone. They also reflect which patients the clinic accepts.
A centre may report higher results if it declines patients with very low ovarian reserve, advanced age, severe male-factor infertility, significant medical conditions, or repeated previous failures.
Another centre may accept complex cases while explaining that expected outcomes are limited. Its overall percentage may be lower because its patient population is different.
Neither a high nor low number can be interpreted fairly without understanding patient selection.
Ethical care should not exclude every difficult patient merely to protect a statistic. At the same time, accepting treatment from a patient with an extremely limited chance without honest counselling is not compassionate.
Jinemed’s approach is to review the individual case, discuss realistic expectations, and avoid using either acceptance or refusal as a marketing tool.
Own Eggs, Donor Eggs, and Different Biological Questions
Success rates using a patient’s own eggs cannot be compared directly with rates using donor eggs.
When donor eggs are used in countries where the treatment is permitted, outcome is strongly influenced by the donor’s age and egg characteristics rather than the recipient’s ovarian age. Combining donor and own-egg cycles can make a programme’s overall rate appear higher while providing little information to a patient planning treatment with her own eggs.
The same caution applies to donated embryos, gestational-carrier cycles, fertility-preservation cases, and patients undergoing genetic testing for a specific inherited condition.
Each pathway represents a different clinical population and should be reported separately.
For treatment at Jinemed in Türkiye, recommendations and procedures must remain within applicable national regulations. International data involving treatments unavailable under Turkish law should not be used to suggest that the same options or outcomes apply locally.
Fresh and Frozen Transfers
IVF outcomes may be reported separately for fresh embryo transfer and frozen embryo transfer.
A fresh transfer occurs during the same ovarian-stimulation cycle as egg collection. A frozen transfer takes place later after an embryo has been vitrified and warmed.
The patient groups are not always comparable. Some patients undergo frozen transfer because genetic testing was performed, because a freeze-all strategy was medically appropriate, or because several good-quality embryos were available. Others may have only one embryo and proceed with fresh transfer.
A high frozen-transfer success rate may therefore reflect selection. Only patients who produced embryos suitable for freezing and later returned for transfer are included.
Fresh and frozen transfer statistics can both be useful, but neither should be interpreted without the treatment context.
The more patient-centred question is often: “What is the chance of a live birth from all embryos created during one egg collection?”
Cumulative Live-Birth Rate
One ovarian stimulation and egg collection may produce more than one embryo. A patient may have a fresh transfer followed by one or more frozen embryo transfers.
Cumulative live-birth rate considers the outcome of all transfers arising from the same egg collection. This can provide a more complete picture of the value of an IVF cycle than the result of the first transfer alone.
For example, a patient may not become pregnant after the first transfer but later have a live birth using a frozen embryo from the same collection. Evaluating only the first transfer would describe the cycle as unsuccessful even though the egg collection ultimately resulted in a child.
Cumulative reporting also has limitations. Complete results may take years to emerge because some patients delay using frozen embryos, move to another clinic, become pregnant naturally, or cannot be reached for follow-up.
Nevertheless, when follow-up is reliable, cumulative live birth is among the most meaningful ways to understand the complete reproductive potential of an egg collection.
Cycle Cancellation and No-Transfer Outcomes
Cycle cancellation is not always evidence of poor care.
Treatment may be cancelled because of inadequate ovarian response, premature ovulation, medical risk, an excessive response that creates concern for ovarian hyperstimulation syndrome, or another unexpected clinical finding.
In some circumstances, cancellation protects the patient from unnecessary procedures or risk. In others, proceeding to egg collection despite a low response may still be reasonable after discussion.
What matters is that cancellation criteria are medically justified, communicated clearly, and included when outcomes are reported from cycle start.
The same applies to cycles with no mature egg, no fertilisation, no blastocyst, or no embryo suitable for transfer. These outcomes are painful, but excluding them from the data creates an incomplete picture of IVF.
A programme committed to transparency learns from every stage—not only from successful transfers.
PGT and the Transfer-Rate Illusion
Preimplantation Genetic Testing for Aneuploidy, or PGT-A, may identify embryos reported as chromosomally suitable for transfer.
Transfer of a selected euploid embryo may have a higher chance of implantation than transfer of an untested embryo of unknown chromosome status. However, reporting only the success rate per euploid embryo transfer begins after several earlier filters:
- Eggs had to be collected
- Mature eggs had to fertilise
- Embryos had to reach blastocyst
- Biopsy had to produce a result
- At least one embryo had to be reported as suitable
Patients who produced no blastocyst or no euploid embryo are not included in the transfer rate.
PGT-A does not create normal embryos and cannot reverse age-related changes in eggs. A high live-birth rate per euploid transfer should not be presented as the patient’s chance from the start of IVF.
For a patient with few embryos, the decision to test requires individual counselling. The appropriate measure remains the likelihood of live birth across the complete treatment pathway, not only after successful selection.
Multiple Pregnancy Is Not a Better Success
Historically, transferring several embryos increased the chance that at least one would implant, but it also increased twin and higher-order multiple pregnancies.
Multiple pregnancy carries higher risks for the mother and babies, including premature delivery, low birth weight, pregnancy-related hypertension, diabetes, and neonatal complications.
For this reason, the optimal outcome of IVF is generally a healthy singleton birth rather than the highest possible pregnancy rate per transfer.
A clinic that transfers more embryos may report a higher short-term pregnancy rate while exposing patients to greater risk. Responsible outcome evaluation should therefore consider:
- Number of embryos transferred
- Singleton and multiple birth rates
- Gestational age at delivery
- Maternal and neonatal safety
Success should include how pregnancy is achieved, not only whether it begins.
Small Numbers and Statistical Uncertainty
Clinic rates may change substantially when only a small number of cycles or transfers are included.
If a clinic performs ten transfers and has five births, the reported rate is 50%. One additional birth or loss changes the percentage markedly. A much larger programme produces a more stable estimate, but patient differences still matter.
Small differences between clinics may reflect chance rather than a genuine difference in quality. Reliable comparisons should consider sample size, confidence intervals, time period, age distribution, treatment type, and whether the data were independently verified.
A rate that appears several percentage points higher is not automatically evidence that one clinic is medically superior.
Patients should also check whether the data describe the most recent complete year. Live-birth reporting necessarily follows treatment with a delay because pregnancies must reach delivery.
International Patients and Missing Follow-Up
International programmes face an additional challenge: patients often return home shortly after embryo transfer.
The clinic may receive the initial pregnancy test but not later ultrasound, miscarriage, delivery, or neonatal information. Some patients stop responding after treatment, particularly when the result is negative.
If follow-up is incomplete, a clinic may know its biochemical pregnancy rate but not have a reliable live-birth rate.
Jinemed and IVF Turkey’s international patient pathway therefore requires structured follow-up:
- Pregnancy blood-test result
- Early ultrasound findings
- Ongoing pregnancy status
- Pregnancy loss when it occurs
- Delivery date and outcome
- Singleton or multiple birth
Collecting this information is not merely administrative. It improves counselling, quality assessment, and the honesty of future reporting.
When live-birth follow-up is incomplete, that limitation should be stated rather than replaced by a pregnancy percentage labelled as success.
Laboratory Quality Beyond Pregnancy Rates
Pregnancy and live birth are the ultimate patient outcomes, but a laboratory also monitors intermediate quality indicators.
These may include:
- Egg maturity
- Normal fertilisation
- Embryo development
- Blastocyst formation
- Survival after vitrification and warming
- Biopsy and sample-identification accuracy
- Incubator and environmental monitoring
- Witnessing, traceability, and documentation
- Adverse events and corrective actions
These indicators help identify whether a problem occurs repeatedly at a particular stage. They should be interpreted by patient group and clinical context rather than used as isolated marketing claims.
A laboratory cannot control egg age or every biological event. It is responsible for providing stable conditions, consistent protocols, accurate handling, and honest review of its own performance.
At Jinemed, laboratory success is understood as protecting every available opportunity while respecting what biology cannot guarantee.
Process Quality Matters
Two patients with the same outcome may experience very different standards of care.
A negative result after careful evaluation, safe treatment, clear communication, and appropriate laboratory work is medically different from a cycle marked by errors, poor information, unnecessary procedures, or unrealistic promises.
Process quality includes:
- Correct diagnosis and treatment selection
- Individualised stimulation
- Medication safety
- Prevention and management of complications
- Laboratory identification and quality control
- Appropriate embryo-transfer strategy
- Informed consent
- Transparent costs
- Psychological and communication support
- Follow-up after success and failure
No process can guarantee a baby. A high-quality process ensures that the patient’s medical opportunity is handled responsibly and that avoidable harm is minimised.
Success After an Unsuccessful Cycle
An unsuccessful cycle should produce more than disappointment. It should also produce information.
The team can review ovarian response, egg maturity, fertilisation, embryo development, transfer conditions, and any pregnancy findings. The next decision may be to repeat the plan, modify it, investigate a specific concern, pause treatment, or decide that another cycle offers very limited benefit.
Recommending every available test after one failure is not evidence-based. Neither is repeating the same plan indefinitely without review.
The quality of a fertility centre is visible in how it responds when treatment does not work. Does it explain the findings? Does it acknowledge uncertainty? Does it resist selling unproven add-ons? Does it respect the patient’s decision to stop?
These questions are part of success even though they cannot be reduced to a percentage.
What Jinemed Means by Success
At Jinemed, success begins with a healthy live birth as the desired medical outcome, but it is not limited to counting positive pregnancy tests.
It also means:
- Giving patients an individual estimate rather than a misleading clinic average
- Reporting outcomes with clear definitions
- Including difficult and unsuccessful stages in quality review
- Prioritising singleton pregnancy and safety
- Maintaining laboratory standards and traceability
- Avoiding unnecessary treatment and unsupported promises
- Communicating honestly when prognosis is limited
- Learning from every cycle
- Supporting patients regardless of outcome
The most honest answer to “What is your success rate?” is often another question:
“Which success rate, for which patients, measured from which stage, and over what period?”
Only after those details are clear does a percentage become meaningful.
IVF statistics describe populations. They do not write the future of an individual patient. Jinemed’s responsibility is to use those statistics with scientific integrity, combine them with the patient’s own medical information, and protect hope from becoming a promise.